According to The New England Journal of Medicine, investigators at Uppsala University Hospital implanted a product called ...
CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback